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NE of the most fascinating syndromes to be recognized in recent years is that of normal-pressure hydrocephalus (NPH). 7' 8,~~
The etiology is poorly understood, and the syndrome remains essentially a diagnosis made by clinical history and neurological examination. Several diagnostic study criteria have proved helpful, but no one of them alone can reliably predict the individuals who will respond favorably to cerebrospinal fluid (CSF) shunting. ~, 3,5,9,12,16,1a The possible usefulness of an assay of the blood levels of intrathecally-injected ~31I-labeled human serum albumin (~sqHSA) as a diagnostic test for impaired protein absorption from the CSF was suggested by Sweet, et al., 2~ in 1954. During the course of studies of CSF dynamics, Tator, et al., 21 reported that radiopharmaceutical blood levels for patients given intrathecal 13qHSA were not appreciably altered in conditions affecting CSF dynamics, although data on actual counts were not reported. However, Abbott and Alksne ~ did report a correlation between radiopharmaceutical levels and hydrocephalus, with significantly lower blood levels being present at around 24 hours after cisterhal injection of lsqHSA in hydrocephalic animals. Interestingly, in three cases of pseudotumor cerebri, the blood levels of CSF-injected ISIlHSA were quite low at 24 hours, and higher values followed treatment of the syndrome. 4 Similar methods for determining any possible obstruction of CSF pro-tein absorption were part of a study ofepsilon aminocaproic acid (EACA) administration to animals with bloody CSF. 6 Below normal venous blood radiopharmaceutical levels have been found in patients who demonstrated transient ventricular filling during the course of cisternography, 15 and a recent report evaluating patients with suspected or actual alterations in CSF flow patterns revealed reduced blood levels of intrathecally-injected radionuclide?
Method
We evaluated 37 consecutive patients with the clinical diagnosis of NPH (of unknown etiology) or Alzheimer's disease undergoing radionuclide cisternography at Duke Hospital between 1969 and 1972. Cisternography was performed in the lateral decubitus position. Each patient received an intrathecal (lumbar) injection of 100 #Ci of 13'IHSA* delivered through a 22-gauge needle with barbotage. The spinal tap was carried out by each patient's staff physician. Spinal fluid protein was assayed in most patients, and was found to be normal.
The intrathecal movement of the radiopharmaceutical was followed at 2, 4, 6, 8, 24, 48, and 72 hours (occasionally longer). Imaging of the cerebral region was performed in all 37 patients studied; imaging of the lumbar region (i.e., site of injection) was included in 33. Imaging was carried out with a commercial Anger scintillation camerat in all but three patients in whom a commercial dual 5-inch detector rectilinear scanner was used.$ When the scintillation camera was used, the scintiphoto images were recorded from the oscilloscope with a Polaroid-Land camera.w Approximately half of these patients had images recorded simultaneously from the other scintillation camera oscilloscope on 35 mm *131I-labeled human serum albumin prepared by Abbott Laboratories, Waukegan, Illinois, as "R1SA-131" (high specific activity), containing less than 2 mg of albumin per injected dose.
tPho-Gamma III Scintillation Camera made by Nuclear Chicago, Des Plaines, Illinois.
SDual Five Rectilinear Scanner, Model 54, made by Ohio-Nuclear Corporation, Mentor, Ohio.
w Automatic 320 Land Camera manufactured by Polaroid Corporation, Cambridge, Massachusetts. film with a Nikon F camera.** During the early studies, patients were so studied at approximate intervals using a fixed number of total count accumulated as the factor determining the interval for recording the data.
To provide a better estimate of the relative interval change in tracer concentration, later scintillation camera imaging studies used for the subsequent images the same time required to record 10,000 counts at the first imaging studies. In all instances, the scintillation camera was calibrated and checked daily for evidence of significant changes in imaging parameters by using a known "flood" source and a fixed technique. The patient's head was positioned in the anterior and lateral projections on succeeding imaging periods in as identical a manner as was attainable. Routine scan technique was employed for the three cases studied with the dual detector rectilinear scanner. Daily instrument calibration was performed. The cisternogram studies were all reviewed and interpreted at one time without knowledge as to the ultimate clinical diagnosis. The cisternogram was subdivided into four levels of CSF passage (Fig. 1) , and abnormal studies were accordingly described as: 1) slow passage through all four levels, 2) arrest or blockage of flow at a given level, or 3) transient or persistent ventricular filling by the radiopharmaceutical (Fig. 2) .
Venous blood samples were drawn frequently during the first 8 hours, at 24 hours, daily for usually 3 days and occasionally longer. Two ml of each blood sample along with an injection standard (a 1:1000 dilution of the injected dose), were counted in a conventional well counter and spectrometer system. To permit comparison of data from one patient with another, the blood concentrations were expressed as the % injected dose • 10 3/ml blood/kg body weight. A sample of the injection standard and blood samples from a limited number of study patients were dialyzed using a microtechnique previously described, 6 which permits determination of the non-albumin-bound ~s~I (dialyzable) present in the 1~1I HSA injection standard and the blood samples taken subsequently. In another four patients, 100 #Ci of 125I sodium iodide were instilled into the subarachnoid space **Nikon F 35 mm camera made by Nippon Kogaku K. K., Tokyo, Japan. Diagnostic differentiation of N P H and Alzheimer's disease FtG. 1. Serial scintiphotos selected from a routine cisternography study (anterior projection) to show the "levels" used in defining progression of the tracer.
along with the ~alI HSA. This was done to permit a direct assay of the appearance in the blood of intrathecally-injected free, nonprotein-bound 12~I.
Fractional pneumoencephalography was carried out in most cases, sometimes before and at other times after cisternography. When there was a choice available, the cisternogram was performed prior to pneumoencephalography; otherwise, a 6-to 7-day interval was observed between these studies. Measurements were made of the callosal angle T M between the ventricles and of the cerebral mantle; this is the distance on the brow-up lateral film from the most anterior part of the lateral ventricle forward to the inner table of the skull, CSF pressure recordings were made during the lumbar puncture for either cisternogram or pneumoencephalogram.
The clinical course of each patient was followed by chart review since few of the patients were under the direct care of the authors.
Results
A total of 37 patients were studied and evaluated as completely as the available data would permit (Tables 1 and 2 ). The normal control values for laqHSA movement from CSF to blood is not readily available. However, from various sources, estimates have been made of the blood levels of F~. 2. Case 4. A transmission emission Anger scintillation camera study illustrating an abnormal CSF circulation pattern at 24 hours, Note the tracer activity within the lateral ventricles and the absence of tracer activity over the convexity. Fig. 1 ). Extravasations graded 0 to 4+, in increasing severity; no symbol means that the area was not scanned. UN = unsatisfactory study.
:~BC=no air beyond basal cisterns; SC=no air beyond Sylvian cisterns; + to +++=degree of sulcal air (++ being normal). Ventricular enlargement was present in all patients except Case 4. radiopharmaceutical at 24 hours following intrathecal injection: 36% to 45% of the injected dose in dogs, 1'6,2s 64% of the injected dose in a treated pseudotumor patient, 4 17.8X l0 s cpm/ml in demented patients?
In our own experience, the most accelerated movement of radiopharmaceutical from CSF to blood occurred during the first 24 hours after intrathecal injection, with a tendency to plateau over 48 to 72 hours and then decline. This pattern was consistently present in a small group of patients without NPH/Alzheimer's disease (Fig. 3) . Although only 24-hour post-injection blood radionuclide activity levels are shown for the NPH/Alzheimer's patients in Tables 1 and 2 , blood samples were evaluated before and after that time in most cases, and peak levels were reached at 24 hours in these cases as well. The 37 patients studied showed a bimodal distribution when their 39 blood level values were plotted statistically. The NPH patients tended to have blood levels lower than those diagnosed as having Alzheimer's disease. In patients with a diagnosis of NPH the average blood level value (sample mean) was 0.049% X 10 8/ml/kg, and 96% of the NPH blood level values were between 0.0068% and 0.091% of the injected dose X 10 3/ml/kg. The patients with Alzheimer's disease had an average blood level value (sample mean) of 0.090% x IO3/ml/kg, while 96% of the Alzheimer's blood level values were between 0.0% and 0.186% of the injected dose X 10 ~/ml/kg. While there was considerable overlap at the lower blood level values the average blood level values (sample means) of the two patient groups were significantly different at p < 0.01. This implies that these groups do in fact represent distinct patient populations although there is considerable overlap of the populations at lower blood radionuclide values. In this series, a radionuclide value greater than 0.091 had only a 2% probability of being within the NPH patient population. A level greater than 0.091 was most likely from a patient with Alzheimer's disease.
The opportunity to repeat the radionuclide cisternogram arose twice (Cases 17 and 26). In one patient with clinical evidence of NPH (Fig. 4) , a consistent low blood radionuclide value was present at 24 hours in both studies. The 48-hour value was considerably less with (Fig. 1) . Extravasations graded 0 to 4+, in increasing severity; no symbol means that the area was not scanned. UN=unsatisfactory study.
:~BC=no air beyond basal cisterns; SC=no air beyond Sylvian cisterns; + to +4-+ =degree of sulcal air (+4-being normal). Ventricular enlargement was present in all patients except Case 2. In several instances, blood samples and/or a standard of the injected lsqHSA were dialyzed to determine what percentage of the measured radioactivity represented nonalbumin-bound, dialyzable x3tI. Table 3 illustrates that in three different batches the percentage of aallHSA standard dialyzable in vitro over a 24-hour period was variable. It was also temperature-dependent since the higher the dialyzable temperature, the larger the percentage dialyzed. It was subsequently found that the the majority of the free as~I was 
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removed during the first hour of dialysis; during a second hour of dialysis, 1/10 of the percentage separated during the first hour was added. The percentage of the standard HSA preparation found to be dialyzable is comparable to the percentage identified by radiochromatography as free x31I (0.6% to 2.1%). The dialyzable (non-albumin-bound) 13~I from the blood of patients given intrathecal ~"qHSA reached its peak during the first hour following injection, and the actual quantities of dialyzable aaaI per ml of blood were always quite small (Fig. 3) . In instances in which the injected ZsqHSA might contain a relatively high percentage of dialyzable zszI (i.e., the 8.5% of normothermia of Batch 1, Table 3 ), it is conceivable that a correspondingly high percentage of the injected radioiodine could rapidly leave the CSF compartment and be taken up by the thyroid and other tissues or excreted, thus never allowing very high elevations of ~sxI to accumulate in the blood. In other words, the 24-hour blood radioiodine counts represent essentially all albumin-bound radioactivity, although a significant percentage of the originally injected ~"qHSA may have been non-albuminbound and lost to assay. To test further this hypothesis regarding the behavior of non-albumin-bound iodide, ~2~I sodium iodide was injected intrathecally in four patients at the same time as ~qHSA instillation. The peak of the ~2~I in blood occurred prior to the 24-hour sample (Fig. 5) , a pattern similar to that for dialyzable 13q from the ~sqHSA standards. Thus, in any given case in which a significant portion of the intrathecally-injected radioactivity is non-albumin-bound, the probability exists that a considerable portion of the injected radioiodine would leave the CSF during the first few hours following intrathecal injection; a proportionally smaller quantity of radioactivity would remain as albumin-bound material to peak in the circulation at 24 to 48 hours.
Cisternograms were considered normal if the radiopharmaceutical reached a significant concentration in the basal cisterns (level 1) by 4 hours, the Sylvian cisterns (level 2) by 6 hours, the lateral convexity (level 3) by 24 hours, and the parasagittal convexity (level 4) by 24 to 48 hours (Fig. 1) . Furthermore, normal studies showed no evidence of either transient or persistent ventricular concentration of the radiopharmaceutical. Abnormal studies consisted of those with slow passage of the radioactive tracer around the convexities, arrest or blockage of radiopharmaceutical flow prior to reaching level 4, and/or transient or persistent ventricular filling. Transient ventricular filling was defined as the presence of radiopharmaceutical in the region of the lateral ventricles at 4 hours but not at 24 hours. A cisternographic diagnosis of NPH was made if there was delayed or arrested passage of the radioactive tracer plus persistent ventricular filling. In none of these cases was there persistent ventricular tracer concentration without slow or arrested passage of tracer over the convexities.
Significant extravasation at the lumbar injection site was found in 16 (48%) instances, and it appeared to be considerable (4+) in eight (24%) of those ( comparable to the 24% incidence of extravasation reported by Kieffer, et al. 15 The occurrence of lumbar extravasation undoubtedly represented leakage of radiopharmaceutical at the needle puncture site but did not seem dependent upon an elevated CSF pressure. The lumbar injection site was monitored in all four unsatisfactory cisternograms, and three showed significant extravasation. For some yet unexplained reason, the instances of extravasation o ccurred almost exclusively in patients with Alzheimer's disease ( Table 2 ). The occurrence of extravasation was not associated primarily with either low-venous high-blood radionuclide levels or abnormal cisternographic patterns. Since the termination of this study, we have elected to add 2 ml of sterile 10% dextrose solution to the radiopharmaceutical at the time of the intrathecal injection as suggested by Halpern, et al. ~2 This has significantly decreased the incidence and degree of radiopharmaceutical extravasation. It was surprising that 12 patients had no CSF pressure recorded in their charts during the course of their entire workup and clinical management. One of these cases was treated as NPH and 11 as Alzheimer's disease.
Comparison of the radiopharmaceutical blood level at 24 hours with the cisternogram data was particularly interesting since these data were available on essentially all but three patients. Twelve of the 15 cases interpreted clinically as NPH had cisternograms which were abnormal in that they showed delayed or arrested passage and persistent ventricular filling. In 14 cases the 24-hour blood radionuclide levels were 0.091% of the injected dose • 10-3/ml/kg, or less in 14 cases. The one NPH patient (Case 32) with what was considered a normal 24-hour blood radionuclide level had an unsatisfactory cisternogram. Four (Cases 9, 11, 18, 26) of the 22 Alzheimer's disease patients had abnormal cisternograms and 24-hour blood radionuclide levels of 0.091% of injected dose • 10-~/ml/kg, or less. In addition, eight (Cases 2, 10, 14, 19, 21, 22, 23, 27) with Alzheimer's disease had low blood radionuclide levels but normal cisternograms, and five (Cases 28, 30, 31, 35, 36) had normal blood radionuclide levels but abnormal cisternograms, of which only one (Case 35) had the cisternographic pattern of NPH.
Discussion
The premise at the onset of this study was that data indicative of the CSF-to-blood ls~I HSA movement at the time of cisternography might be helpful in selecting cases of NPH and distinguishing them from cases of Alzheimer's disease. The mean blood radionuclide level (% injected dose • 10-8/ml/kg) at 24 hours following intrathecal injection was 0.049 for NPH patients, while the mean was 0.090 for Alzheimer's patients (a statistically significant difference at p < 0.01). If a blood radionuclide level greater than 0.091 were found, there would exist only a 2% probability that such a patient would have NPH. It may be useful in future clinical studies of this nature to dialyze routinely a sample of the XsqHSA used for intrathecal injection as well as the blood samples drawn later. This should permit expression of the 181I HSA blood levels as % injected nondialyzable dose/ml blood/kg of body weight and may thus define more accurate values for both the NPH and Ahheimer's patient populations.
The recent report of Behrman, et al.? includes an experimental design not dissimilar from our own. Although two different patterns of CSF-to-blood movement of xs~I HSA were described in 51 demented patients, no additional supportive data were mentioned to justify the conclusion that the group of patients with slow movement were, in fact, patients with NPH. Indeed, only two patients in the slow movement group were shunted. Only "a few" of the patients had accompanying cisternography, and the potential problem of non-albumin-bound xsxI in the injected ~sqHSA was not considered. Therefore, we would be reluctant to accept their implication that slow movement was synonymous with NPH.
The several other objective criteria studied in our series included the following: 1) cisternography, with abnormal patterns for NPH including a block or delay in the flow of radiopharmaceutical and persistent ventricular filling; 2) pneumoencephalography, with hydrocephalus associated with an arrest of flow of air at a given anatomical location; 3) the cerebral mantle thickness 40 mm or less being abnormal; 4) the callosal angle, less than 120 ~ being abnormal.
The purpose of this study was to apply and relate the various objective criteria mentioned above to the clinical impressions assigned to these patients. A comparison of the frequency of abnormality in these parameters is shown in Table 4 . Of the NPH cases, 86% of the cisternograms and 100% of the pneumoencephalographic air passage studies (when performed) were abnormal. Smaller percentages of NPH cases had abnormal cerebral mantles and callosal angles. Of these criteria, perhaps the most abstract is the interpretation given to cisternography. With particular reference to NPH, the importance of the finding of both persistent ventricular retention of the radiopharmaceutical and basal retention without parasagittal accumulation has been stressed by others. 7' 1s' 14' 19' 22 Slow passage of the radiopharmaceutical over the convexities has been noted ~8'"'19 but its significance, along with that of transient ventricular retention, 7 is still debated.
With regard to the 22 patients who presented clinical evidence of Alzheimer's disease, 23% of the technically satisfactory cisternograms were abnormal showing patterns compatible with NPH, and half of the pneumoencephalograms showed abnormal air flow patterns. The cerebral mantle was abnormal in 33% of the studies and the callosal angle in 44%. The low blood radionuclide concentrations but normal cisternograms in eight instances of Alzheimer's disease might result from either an otherwise unrecognized actual impairment in CSF albumin movement or a technical artifact related to a possible high percentage of dialyzable, non-albumin-bound lsq in the 131I HSA preparation. In the absence of dialysis data for each of these cases, it is impossible at this time to rule out the latter possibility. No shunting procedures were done on these eight patients. The occurrence of altered CSF flow Diagnostic differentiation of NPH and Alzheimer's disease patterns demonstrable by cisternography even though the CSF-to-blood ~31IHSA movement seemed adequate in four cases of Alzheimer's disease remains a puzzlement; none had any shunting procedure done.
There were four instances of consistently abnormal cisternograms (compatible with NPH) and low blood isotope concentrations in patients treated clinically for Alzheimer's disease. A shunt procedure was done on only one (Case 26) of these patients although studies strongly suggested NPH rather than Alzheimer's disease as the correct diagnosis.
Although an evaluation of the clinical response of NPH patients to the shunt procedure is not the primary aim of this study, brief mention will be made of the follow-up (2 mos to 2 yrs) clinical impressions of both the NPH and Alzheimer's disease patients. Nine of the NPH patients were shunted; five (56%) improved, three did not change, and one, the patient with the most abnormal blood radioiodine value, became worse. In four of the patients with NPH, a shunt was not used; three of these did not change and one improved. Of the 21 Alzheimer's disease patients without shunts, two (9%) were improved, one was worse, 17 (81%) did not change, and one has had no follow-up. The one Alzheimer's disease patient with a shunt did not improve.
Summary
Studies are reported that attempt to relate alterations in CSF-to-blood radiopharmaceutical movement to abnormal cisternographic CSF flow patterns in 37 patients with dementia (Alzheimer's disease versus NPH). Patients suspected clinically of having NPH all had abnormal pneumoencephalography (when performed), 86% had cisternographic patterns compatible with NPH, and 24-hour radionuclide blood levels had a mean value of 0.04% of the injected dose • 10S/ml/kg. The clinical examples of Alzheimer's disease had abnormal cisternograms in 23%, abnormal air passage patterns in 50%, and a mean 24-hour radionuclide blood level of 0.090% of the injected dose • 10-8/ml/kg. It was concluded that any patient being evaluated for NPH versus Alzheimer's disease whose blood level of radionuclide 24 hours after intrathecal injection was greater than 0.091 probably did not have NPH, and that the combined finding of a low blood radionuclide level with abnormal pneumoencephalography and cisternography gave the strongest positive evidence for NPH.
